Eikon Therapeutics, Inc. (EIKN) Stock Forecast
EIKN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 6 analysts
- Price target
- $24.33 average of analyst targets
- Upside to target
- +227.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-1.74
- 52-week range
- $6.72 – $16.26
EIKN analyst ratings
6 analystsNumber of analysts at each rating.
EIKN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EIKN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.60 | −$1.74 | −$1.33 | — | — | 5 |
| Current fiscal year (2026) | −$6.58 | −$7.40 | −$5.84 | −$115.29 | +94.3% | 6 |
| Next fiscal year (2027) | −$6.69 | −$8.49 | −$4.86 | −$6.58 | −1.8% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EIKN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
EIKN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EIKN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.56 | −$1.52 | −$1.58 | −$1.58 | −$1.60 | +3.1% | 2 up · 1 down |
| Current fiscal year (2026) | −$6.35 | −$6.41 | −$6.41 | −$6.41 | −$6.58 | +3.6% | 2 up · 1 down |
| Next fiscal year (2027) | −$6.19 | −$6.33 | −$6.33 | −$6.33 | −$6.69 | +8.2% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EIKN earnings surprises
Reported EPS vs the consensus estimate for the last 3 quarters; EIKN beat in 0 of 3.
What analysts expect from EIKN
6 analysts cover Eikon Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.33, 227.9% above the latest close of $7.42. Analysts expect earnings of −$6.58 per share for 2026, +94.3% from a year earlier. For 2027 the average estimate is −$6.69 per share. Eikon Therapeutics beat the EPS estimate in 0 of the last 3 quarters.
Related: EIKN income statement, EIKN key metrics, EIKN chart. See the EIKN stock overview for the latest quote and news.
EIKN forecast FAQ
What is Eikon Therapeutics's price target?
The average analyst price target for Eikon Therapeutics is $24.33, 227.9% above the latest close of $7.42.
Is Eikon Therapeutics a buy, hold or sell?
Of 6 analysts covering Eikon Therapeutics, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eikon Therapeutics's EPS forecast?
Analysts forecast −$6.58 per share for 2026 (range −$7.40 to −$5.84); for 2027 the estimate is −$6.69.
When does Eikon Therapeutics report earnings?
Eikon Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-1.74.
Does Eikon Therapeutics usually beat earnings estimates?
Eikon Therapeutics reported EPS at or above the analyst estimate in 0 of the last 3 quarters.